News

News

ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that the European Commission has granted Orphan Drug Designation to ZYNLONTA®, a CD19-targeted ADC, for the treatment of diffuse large B-cell lymphoma (DLBCL).

9/13/2021

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners (HealthCare Royalty).

8/26/2021

LiquiGlide Unveils Transformative Zero-Waste Packaging for the Health and Beauty Industry

LiquiGlide, the inventors of a breakthrough technology that is revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, has announced the launch of zero-waste packaging for the health and beauty industry.

8/24/2021

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZO™ (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).

8/20/2021

Transparency Life Sciences Rebrands as Drumroll Health and Launches New AI-Powered Patient Insights Platform

Transparency Life Sciences, a digital health startup that develops technology solutions to foster closer partnerships between patients and health professionals, today unveiled a new corporate identity and company name: Drumroll Health.

8/10/2021

Cibus and GDM Establish Strategic Partnership to Deliver New Solutions for Soybean Farmers

Cibus, a leader in precision gene editing in agriculture, and GDM, a leading global soybean research company, today announced a strategic collaboration focused on developing and delivering new solutions for challenges faced by soybean farmers.

7/7/2021

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

FibroGen, Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion relating to the use of roxadustat for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).

6/25/2021

LiquiGlide Announces FDA Device Master File (MAF) for Its Breakthrough Technology to Enable Accelerated Development of Medical Devices

LiquiGlide, the inventors of a breakthrough technology that's revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, has announced that the U.S. Food and Drug Administration (FDA) has accepted a Device Master File (MAF) from LiquiGlide's biomedical division for its novel, patented coating platform.

6/16/2021

ROYALTY PHARMA ANNOUNCES $2.025 BILLION STRATEGIC FUNDING PARTNERSHIP WITH MORPHOSYS

Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This partnership is expected to fuel the expansion of the combined company’s capabilities to help enable the development and potential approvals of important cancer treatments.

6/2/2021

ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA™ (loncastuximab tesirine-lpyl) has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines) in oncology for B-cell Lymphomas.

5/6/2021

Cibus Welcomes the European Commission’s Landmark Study on New Genomic Techniques (NGTs) that Includes Cibus’ Gene Editing Technologies

SAN DIEGO – May 4, 2021 – Cibus, a leader in precision gene editing and trait development in agriculture, welcomes the published findings of the European Commission’s New Genomics Techniques (NGTs) study.

5/5/2021

Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Applications (sNDAs) for lumateperone, an investigational agent for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate.

5/3/2021

LiquiGlide Announces New Partnerships and Latest Funding Round as Frictionless Future Becomes a Reality

The company's $13.5M round and additional partnerships with Colgate, the Mibelle Group and Yves Béhar prove technology's ability to create market-viable solutions for no-waste products, packaging, and manufacturing processes.

4/27/2021

Colgate's New High-Tech Nonstick Toothpaste Tubes Help You Squeeze Out Every Drop

Today LiquiGlide, the company spun out of MIT’s Varanasi Research Group to develop ways to manufacture and commercialize the technology, announced a new $13.5 million round of funding. But more importantly for consumers, the company also revealed a new partnership with Colgate.

4/27/2021

ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA™ (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma.

4/23/2021

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD).

4/15/2021

FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD).

4/12/2021

VERIGRAFT was selected as a finalist in the 2021 Lyfebulb-CSL Behring Innovation Challenge

The goal of the 2021 Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation is to source innovative solutions to improve outcomes and experiences for all those affected by transplantation.

4/8/2021

Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million

Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments.

4/8/2021

1910 Genetics Debuts with $26M to Accelerate the Design of Small Molecule and Protein Therapeutics Through AI, Computation and Biological Automation

Backed by M12 - Microsoft's Venture Fund and Playground Global, 1910 Genetics will scale its AI and biological automation platforms, build its world-class team, expand partnerships with biopharma companies and advance its pipeline of therapeutic programs

3/23/2021